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Abstract
Niemann-Pick type C2 (NPC2) disease is a fatal autosomal recessive neurovisceral degenerative disorder characterized by
late endosomal-lysosomal sequestration of low-density lipoprotein derived cholesterol. The breach in intracellular
cholesterol homeostasis is caused by deficiency of functional NPC2, a soluble sterol binding protein targeted to the
lysosomes by binding the mannose-6-phosphate receptor. As currently there is no effective treatment for the disorder, we
have investigated the efficacy of NPC2 replacement therapy in a murine gene-trap model of NPC2-disease generated on the
129P2/OlaHsd genetic background. NPC2 was purified from bovine milk and its functional competence assured in NPC2-
deficient fibroblasts using the specific cholesterol fluorescent probe filipin. For evaluation of phenotype correction in vivo,
three-week-old NPC22/2 mice received two weekly intravenous injections of 5 mg/kg NPC2 until trial termination 66 days
later. Whereas the saline treated NPC22/2 mice exhibited massive visceral cholesterol storage as compared to their wild-
type littermates, administration of NPC2 caused a marked reduction in cholesterol build up. The histological findings,
indicating an amelioration of the disease pathology in liver, spleen, and lungs, corroborated the biochemical results. Little or
no difference in the overall cholesterol levels was observed in the kidneys, blood, cerebral cortex and hippocampus when
comparing NPC22/2 and wild type mice. However, cerebellum cholesterol was increased about two fold in NPC22/2 mice
compared with wild-type littermates. Weight gain performance was slightly improved as a result of the NPC2 treatment but
significant motor coordination deficits were still observed. Accordingly, ultrastructural cerebellar abnormalities were
detected in both saline treated and NPC2 treated NPC22/2 animals 87 days post partum. Our data indicate that protein
replacement may be a beneficial therapeutic approach in the treatment of the visceral manifestations in NPC2 disease and
further suggest that neurodegeneration is not secondary to visceral dysfunction.
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Introduction
Niemann-Pick type C (NPC) disease is a rare autosomal
recessive, lysosomal storage disorder characterized by intracellu-
lar accumulation of cholesterol and other lipids throughout the
body [1,2]. The etiology of the disease resides in mutations that
inactivate either of two proteins, NPC1 (95% of cases) or NPC2
(5% of cases) [3,4]. These two proteins are structurally distinct -
NPC1 is a large transmembrane protein situated in late
endosomes and NPC2 is a small soluble sterol-binding glycopro-
tein (see [5] for a recent review). While the precise function of
these proteins is not completely understood, the resemblance of
both the clinical manifestations and biochemical abnormalities
suggests that they function in concert to facilitate the egress of
lipoprotein-derived cholesterol from the endo-lysosomal system
[6,7,8]. The clinical spectrum of NPC disease is relatively broad,
ranging from a rapidly fatal neonatal disorder to a chronic
neurodegenerative disease with adult onset. Apart from the
approximately 10% of the patients who die before 6 months of
age due to liver- and respiratory failure, most patients ultimately
develop progressive neurological dysfunction, which typically is
preceded by varying degrees of hepatosplenomegaly. Typical
neurological symptoms include vertical supranuclear gaze palsy,
cerebellar ataxia, dysarthria, dysphagia, and progressive demen-
tia [1,9,10].
To date there is no effective therapy for NPC disease, although
encouraging results have emerged from recent preclinical studies
using the sterol chelator 2-hydroxypropyl-b-cyclodextrin (CD) and
the glucosylceramide synthase inhibitor miglustat [11,12,13,14].
Bone marrow transplantation has been attempted in two patients
diagnosed with NPC2 disease. Unfortunately, the first patient died
two months after the procedure from an adenovirus infection [15]
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and a long-term follow up is required before the efficacy of the
second bone marrow transplant can be ascertained [16].
Enzyme replacement therapy (ERT) has previously been used
with variable success in a number of lysosomal storage disorders,
including Gaucher disease, Mucopolysaccharidosis types I, II and
VI, Fabry disease, and Pompe disease [17,18,19]. ERT relies on
the capacity of cells to endocytose exogenously supplied lysosomal
enzymes and transfer them to the lysosomes [20]. This is usually
done via the mannose-6-phosphate (M6P)-receptors and the
mannose receptor. In the initial study elucidating the molecular
basis for NPC2 disease, conditioned medium from Chinese
hamster ovary cells secreting recombinant NPC2 was able to
correct the cholesterol-laden phenotype of cultured NPC2
deficient fibroblasts in a M6P inhibitable manner [4]. Thus, the
NPC2 protein appears a suitable candidate for replacement
therapy and may potentially provide the means to impede and
correct the progression of the disease.
NPC2 is a highly conserved small glycoprotein (approx. 16
KDa), which is present in all mammalian tissues examined [4,21].
In common with many other lysosomal proteins, it is present in
low quantities and cannot be directly purified from tissue in
significant amounts. However, NPC2 is also found in secretory
fluids such as epididymal fluid [22], milk [21], bile and plasma
[23]. Our laboratory originally purified and structurally analyzed
milk derived bovine NPC2, called EPV20 [21]. The protein is
relatively abundant in bovine milk, which facilitates isolation of
quantities sufficient for crystallographic studies [24,25]. Mature
milk derived bovine NPC2 contain 130 amino acid residues, the
same length as the deduced amino acid sequence of its murine
homologue. By comparison, the predicted primary sequence of
human NPC2 is extended with additional two amino acid residues.
The amino acid sequence identity between the milk derived
bovine NPC2 and human NPC2 is 79% and between bovine
NPC2 and murine 75%. In addition, the spatial distribution of the
six cysteine residues known to be involved in intra-chain disulfide
bonds in the bovine protein is the same in the human and murine
counterparts. Also, the secreted bovine protein was capable of
binding to the cation-independent M6P/IGF2-receptor by a
mechanism which could be inhibited by M6P (own unpublished
data) and the cholesterol binding domains essential for ligand
transport are preserve in the milk derived protein [21,24].
Furthermore, the purified protein does not carry the mutations
exhibited in the NPC2 patient population. Taken together, the
structural comparison suggests that milk-borne NPC2 potentially
can complement the loss of endogenous NPC2. The availability of
an abundant source of NPC2 protein and a murine NPC2-
hypomorph animal model have made it possible, for the first time,
to test if NPC2 replacement therapy is a potential therapeutic
strategy for NPC2 disease. The question was explored by
comparison of physical, biochemical and histological alterations
in NPC2 treated NPC22/2 mice, saline mock-treated NPC22/2
mice, and age-matched wild type littermates. Intravenous
injections of bovine NPC2 lead to a marked systemic improvement
in the NPC22/2 mice, although the chosen intervention was
unable to prevent the progressive neurodegeneration associated
with the disease. The results highlight an effective novel approach
for treatment of the visceral manifestations in NPC2 disease.
Materials and Methods
Purification and characterization of NPC2
Naturally occurring NPC2 was purified from bovine skim milk
by selective acid and ammonium sulfate precipitation followed by
a two-step ion-exchange procedure as previously described [21].
The purity and identity of the purified protein was determined by
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) in 10–20%
gradient gels and N-terminal amino acid sequence analysis (ABI
477A/120A, Applied Biosystems Inc.), respectively. Protein
concentrations were determined by acid hydrolysis followed by
quantitative amino acid analysis based on o-phtaldialdehyde
derivation.
Endotoxin removal
Purified NPC2 was dialyzed into endotoxin-free Dulbecco’s
Phosphate Buffered Saline, pH 7.4 (D-PBS) (Gibco). The retentate
was applied to a DEAE-sepharose column equilibrated in D-PBS,
pH 7.4. The quantity of lipopolysaccharide (endotoxin) present in
the flow through NPC2 preparation was determined using a
Limulus amebocyte lysate assay (LAL-assay, Lonza, Inc.) according to
the manufacturer instructions. The purified NPC2 was sterile-
filtered and stored frozen at –20uC until use.
Cell lines and primary embryonic cells
Normal human skin fibroblasts (GM08680) were obtained from
American Type Culture Collection (Rockville, MD, USA). The
NPC2-null mutant human skin fibroblast cell line, NPC2G58T
(NIH 99.04) was a kind gift from Anthony H. Fensom (Paediatric
Research Unit, United School of Guy’s Hospital, London).
Primary mouse embryonic fibroblasts were isolated from 13 days
old fetuses bearing NPC2+/+ and NPC22/2 (129P2/OlaHsd-
NPCGt(LST105)BygNya) genotypes. The head and internal organs
were removed, and the torso was minced and dispersed in 0.1%
trypsin for 10 min at 37uC. All cells were plated in DMEM
containing 10% Fetal Calf Serum (FBS) and 1% penicillin/
streptomycin and routinely maintained at 5% CO2 and 37uC. A
small piece of tissue from each embryo was used to determine the
genotype as described below.
Filipin fluorescence staining of free cholesterol
Fibroblasts were seeded onto glass cover slips in 24-well tissue
culture microplates in DMEM medium containing 10% FCS and
grown to ,80% confluence (86105 cells/well) and then incubated
for 48 hours with 10 mg/ml NPC2 in a 0.5 ml working volume.
To examine the cholesterol load the fibroblasts were fixed in 10%
phosphate buffered formalin, pH 7.2 for 30 min, washed three
times in D-PBS containing calcium and magnesium and then
incubated for one hour with Filipin III (10 mg/ml) in PBS:DMSO
(50:1). Subsequently, the fibroblasts were washed three times in D-
PBS. Coverslips were examined with a Zeiss Axioplan2 imaging
fluorescence microscope equipped with a Axiocam digital camera/
ACT-1 software. Visualization of filipin images was performed
using 360/40 nm excitation and 465/30 emmision filters.
Animals
129P2/OlaHsd-NPCGt(LST105)BygNya mice holding the LST105
mutation were used in the present study. The LST105 mutation
yields a fusion protein that includes the first 27 amino acids of the
NPC2 protein (encoded by the first exon of the NPC2 gene),
including the 19 amino acids signal sequence. Mice heterozygous
for the LST105 gene trap mutation were interbred to obtain
siblings homozygous for the gene trap (NPC22/2) and wild type
(NPC2+/+) alleles. The NPC22/2 and NPC2+/+ littermates were
housed in standard type II and type III plastic cages with filter tops
(Technipast, Italy) at an ambient temperature of 20uC and with
altering 12 hour periods of dark and light. The animals were given
ad libitum access to water and standard low-cholesterol (0.02% w/
w) chow (Altromin 1314, Brogaarden A/S, Gentofte). The
NPC2 Replacement Therapy in NPC2-/- Mouse Model
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experimental protocol was approved by The Danish Experimental
Animal Inspectorate (Permit numbers 561-1407 and 562-25).
Genotyping
All mice were genotyped at postnatal day 16 (P16). DNA from
ear tags was prepared using the N-extract tissue kit (Sigma-
Aldrich; cat. no. XNATR). Polymerase chain reactions (PCR’s)
were performed using the two set of primer pairs (NPC2-mutant:
forward primer 59-CCA GGC AGC ACG GAT GTC-39 and
reverse primer 59-GCC AGG GTT TTC CCA GTC A-39) and
(NPC2-wt: forward primer 59-TGT GGC TCA GTG GCT TAG
G-39 and reverse primer 59-CCA GGA AGG GAT TTC ACA
CA-39). The PCR-products were run on a 1.5% agarose gel in
1xTBE buffer and stained in Midori Green (Nippon Genetics).
Analysis of the gels was performed on a Typhoon scanner (GE
Healthcare).
Measurement of murine immune response to NPC2
For an initial evaluation of the septic potential and antibody
response to infusion of the bovine NPC2 protein preparation, eight
NPC2+/+ mice were equally divided in two groups and challenged
weekly with 5 mg/kg NPC2 injected intraperitoneally (i.p.) or
intravenously (i.v.), respectively. Blood was drawn and serum
isolated before treatment start (pre-immune) and ones a week for
five weeks. The mice were anesthetized with isoflurane before the
blood was sampled from the retro-orbital sinus using a fine-walled
Pasteur pipette (o.d. of 1–2 mm). Anti-NPC2 IgG positive serum
was produced by subcutaneous injections of Freund Complete
Adjuvants mixed with NPC2 protein. The injection was repeated
three weeks later and serum was prepared 6 weeks after the last
immunization. A relative quantification of anti-NPC2 IgG, was
performed using a time-resolved immune fluorometric assays
(TRIFMA); 100 ml purified NPC2 (1 mg/ml) in D-PBS, pH 7.4
was incubated for 18 hours in 96-well microtiter plates at room
temperature (RT). The wells were washed three times in washing
buffer 1 (WB1: TBS, 0.05% Tween 20) and then blocked for one
hour with WB1 at RT. 100 ml purified mouse plasma diluted
1:1000, 1:3000, and 1:9000 in WB1 were added to the NPC2
coated wells and incubated at RT for one hour. After incubation,
the WB1 washing was repeated, followed by one hour incubation
at RT with 100 ml of biotin-conjugated rabbit anti-mouse IgG
(1 mg/ml; DAKO). The primary antibody was removed by
washing in WB1 and rinsing in washing buffer 2 (WB2: TBS,
0.05% Tween 20, 25 mM EDTA). Next Eu3+-conjugated strepta-
vidin (Sigma Aldrich) diluted in WB2 was added to the wells and
incubated for one hour at RT. The wells were washed three times
in WB2 and bound europium was detected on a Delfiar
fluorometer (Perkin Elmer). Anti-NPC2 IgG responses were
calculated by subtracting the mean background signal (buffer
only) from the mean anti-NPC2 IgG signal. Using the same
technique NPC22/2- and wild type mice enrolled in the NPC2
replacement trial were tested for anti-NPC2 activity just before
and weeks 4, 8, and 10 after commencing the NPC2 treatment
trial.
NPC2 replacement therapy procedure
To study the long-term effect of NPC2 replacement therapy on
the disease phenotype we established a colony of NPC2 deficient
(NPC22/2) and wild type (NPC2+/+) siblings from mating NPC2+/2
mice. The offspring were divided into three groups, each
containing ten animals. In the first group, three-week-old
NPC22/2 mice were treated twice/week with a tail vein injection
of 5 mg/kg. In the second group, NPC22/2 control mice received
saline solution. The third group comprised age-matched saline
treated NPC2+/+ littermates. All groups were injected with the
same volume and frequency. Hypersensitivity reactions and
mortality were absent throughout the entire treatment period.
Other possible side effects were monitored by daily inspection of
cage behaviour, food and water consumption. Body weights were
measured once weekly and serum samples were collected every
other week just prior to treatment. At P87, the mice were
euthanatized, and organs (liver, spleen, lungs, kidneys, and brain)
were weighted and secured for biochemical and histological
analyses. Tissue sections used for biochemical analyses were snap
frozen using liquid nitrogen and stored at 280uC, whereas
sections for histological and immunohistochemical examination
were immersion fixed in 4% phosphate buffered paraformalde-
hyde for at least 48 hours.
Histological and Immunohistochemical staining
Paraformaldehyde fixed tissues from three mice in each of the
three experimental groups (NPC2 treated NPC22/2 mice, saline
treated NPC22/2 mice, and saline treated wild type mice) were
placed in PBS overnight and then dehydrated in ethanol and
xylene, and embedded in paraffin. For routine histology, 5 mm-
thick paraffin sections were rehydrated and stained with
haematoxylin and eosin (H&E), periodic acid-Schiff (PAS), or
Masson Trichrome stain. Before histological immunostaining
endogenous peroxidase activity was eliminated by incubation with
3% hydrogen peroxide for 10 minutes and the sections were then
washed in running tap water for 10 minutes. Following heat-
mediated antigen retrieval in Tris-buffer, pH 8.5, sections were
rinsed in PBS-buffer, pH 7.6 and incubated for 30 minutes with
Rat anti-mouse F4/80 antibody (1:100) (Invitrogen). The primary
antibody was removed and the slices washed two times for five
minutes in PBS, pH 7.6, before incubation for 30 minutes with
HRP-conjugated anti-rat immunoglobulin (1:100) (P0450,
DAKO). After repeated rinsing in PBS the sections were stained
with 3.3-diaminobenzidine tetrahydrochloride (DAB) substrate
and counterstained with haematoxylin. The sections were washed
in running tap water, dehydrated and mounted. Brightfield images
were obtained using an upright Leica microscope (DM2500)
equipped with a Leica digital camera (DGC320). An experimenter
blinded to genotype and treatment status undertook all procedures
and post-staining image analyses.
Cholesterol extraction and quantification
Tissue samples were obtained from six mice in each of the three
experimental groups and total cholesterol was extracted by
homogenization in chloroform/methanol (2:1) according to Folch
[26]. Briefly, 10 mg of tissue was homogenized in two ml D-PBS,
pH 7.4, containing a protease inhibitor cocktail with EDTA
(Roche) and 1 mM butylated hydroxytoluene (Sigma Aldrich),
using a tissue lyzer II apparatus (Qiagen). 0.6 mL of the
homogenate was extracted with three volumes of chloroform/
methanol (2:1, v/v). The mixture was vortexed for one min and
centrifuged 10 min at 1000 x g. The extraction of the upper phase
(aqueous phase) was repeated five times and the extract was
concentrated under a stream of nitrogen and re-dissolved with
0.1 mL 2-propanol. Total cholesterol was measured by an
enzymatic, colorimetric, endpoint method according to the
manufacturer instructions (Randox). To determine the reliability
of the colometric method used, each tissue homogenate was
divided in two and each half was analyzed separately. In analyzing
variance, the two samples obtained from each mouse were
averaged. No difference in cholesterol levels per mg wet tissue was
observed between males and females organs. Therefore, the means
NPC2 Replacement Therapy in NPC2-/- Mouse Model
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of total cholesterol in all tissues are generated based on data from
both genders.
Statistical data analysis
Quantitative data were statistically evaluated with one-way
analysis of variance (ANOVA) and analyses were performed on ln-
transformed data. Multiple comparison ad hoc tests were
performed by pair wise comparisons. In order to interpret results
in percentage terms, estimates of differences between groups were
transformed by exp and 95% confidence intervals (CI) were
calculated for these relative differences. To compare the relative
weight change in each of the treatment groups, the relative weight
change from day 70 to 87 was calculated for each animal and the
saline-treated NPC2+/+, saline-treated NPC22/2 and the NPC2-
treated mice were compared by ANOVA. Homogeneity of
variance was tested using Bartletts test. The statistical software
used was STATA version 10 and the significance level was set to
5%.
Results
Preparation and in vitro activity validation of milk derived
NPC2
Endogenous NPC2 was purified from bovine milk by sequential
anion- and cation- exchange chromatography as previously
described [21]. An additional anion exchange chromatography
step was performed to selectively remove or decrease contami-
nating endotoxins from the eluted protein preparation. Upon
electrophoresis in SDS–polyacrylamide gels, the resulting NPC2
migrated as a single band with the expected mobility (apparent
molecular mass of ,20 kDa) (Fig. 1 A). The identity and purity
(.95%) of the NPC2 preparation was further confirmed by N-
terminal Edmann sequencing. Amino acid analysis and Limulus
test revealed that the average yield of purified NPC2 was 2
milligrams per litre of milk, holding less than 5 endotoxin units per
mg protein (data not shown). To confirm the functional
competence of the milk-derived NPC2 preparation we used filipin
fluorescence staining of free cholesterol in cultivated human and
murine fibroblasts. Intense labelling of punctuated vesicular
structures throughout the cytoplasm was observed in human skin
fibroblasts with a null mutation (Glu20stop) in the NPC2 gene as
well as in the primary culture of murine embryonic NPC22/2
fibroblasts developed by mating NPC2-targeted heterozygous
(Fig. 1 B, middle panels). Addition of 600 nM purified NPC2 in the
culture medium corrected the cholesterol storage phenotype in
both the human and murine NPC22/2 fibroblasts, as evidenced by
the marked decrease in filipin fluorescence to a level observed for
the wild type cells (Fig. 1 B, right and left panels). A ten-fold reduction
in the NPC2 concentration, equivalent to <3756105 molecules of
NPC2 added per cell, did not alter this outcome (not shown). The
cross-species correction of defective recipient cells means that the
bovine NPC2 preparations fulfil the first criteria for a successful
introduction of the protein in the murine NPC2 disease model.
Assessment of humoral immune response to bovine
NPC2 in mice
Monitoring of antibody production during protein replacement
therapy is an important consideration as high-titer neutralizing
antibody translates into a lack of clinical response and affect the
safety of the therapy [27]. Thus, as fluorometry based immuno-
assay was designed for the detection of anti-NPC2 IgG in mouse
serum. During the five-week evaluation period, no clinical signs
consistent with a hypersensitivity reaction were observed resulting
from weekly injections of saline or 5 mg/kg NPC2. In some
animals, however, we did see a minor boost in NPC2 specific
antibodies caused by intraperitoneal injection (Fig. 2A). As
intravenous tail vein injections revealed levels of anti-NPC2 IgG
similar to the baseline levels observed in saline-treated mice
(Fig. 2B), we chose this route of administration to study the long-
term effect of NPC2 replacement therapy. During the ten-week
replacement therapy trial (performed as described below), no
hypersensitivity reactions were observed in any of the enrolled
mice. However, Anti-NPC2 IgG in variable amounts was
detectable in the some of the NPC2 treated mice, but the titers
were 20 to 200-fold lower than those observed in serum from
NPC2 immunized mice (Fig. 2C).
NPC replacement therapy reduces weight loss in NPC2-/-
mice
In order to study the efficacy of NPC2 replacement therapy,
offspring of heterozygote NPC2 mutant breeding pairs were
divided into three groups, each containing ten animals. In the first
and second group, three-week-old NPC22/2 mice received NPC2
(5 mg/kg) or saline, respectively, by tail vein injection twice weekly
for 66 days. The third group comprised age-matched saline treated
NPC2+/+ littermates, injected with the same volume and
frequency. A reported common feature of NPC1 gene ablated
and NPC2 hypomorphic mice is rapid weight loss at some point
during the disease progression [8]. In the NPC2 deficient mouse
model used in this study, weight loss commenced at about P70 and
progresses rapidly until termination of the trial at P87. In the
period from P70 to P87, female and male saline treated NPC2+/+
mice gained 7.5% (P|,0.05, 95% CI: 4.0-11.2) and 5.8%
(P|,0.05, 95% CI: 3.7-7.9) in weight, respectively (Fig. 3 A and
B). During the same time period, age matched saline-treated
NPC22/2 female and male mice experienced a weight loss of
15.4% (P|,0.05, 95% CI: 10.8–19.9) and 16.9% (P|,0.05, 95%
CI: 12.2–21.8), respectively. In comparison to the saline treated
NPC22/2mice, the weight loss observed in NPC2 treated NPC22/2
mice was significantly reduced and amounted to 6.9% in females
(P|,0.05, 95% CI: 3.5–10.3) and 6.4% in males (P|,0.05, 95%
CI: 1.0–13.8) during the P70 to P87 period. Our results suggest
that NPC2 replacement therapy partially reversed the NPC2
disease induced reduction in body weight. Whether this effect is
subscribed to an enhanced organ function and dietary metabo-
lism or the result of improvement of motor and e.g. swallowing
function, is beyond the scope of the present report and merits
further investigations.
NPC2 treatment partially corrects visceral cholesterol
accumulation in NPC22/2 mice
Visceral cholesterol accumulation is a hallmark of NPC disease
[1,8]. Liver cholesterol content was 12.2 fold (P|,0.05, 95% CI:
9.1–16.4) higher in saline treated NPC22/2 mice compared with
age-matched wild type littermates. NPC2-treated NPC22/2 mice
showed a 6.2 fold (P|,0.05, 95% CI: 4.5–8.4) reduction in liver
cholesterol levels of that found in the vesicle treated NPC22/2
mice (Fig. 4). Accumulated storage material was also observed in
the spleen of saline treated NPC22/2 mice where the cholesterol
level on averages was 10.3-fold higher than in wild type spleen
(P|,0.05, 95% CI: 5.6–18.9). However, the amount of cholesterol
entrapped in the spleen of treated NPC22/2 animals, was reduced
by 5.0 fold (P|,0.05, 95% CI: 2.8–8.9) (Fig. 4). Notably,
accumulated cholesterol was also reduced efficiently in the lung
where the cholesterol level in the saline treated NPC22/2 mice was
6.8 times (95% CI: 4.3–10.6) higher than detected in wild type
mice. NPC2 treatment led to a 2.4 fold reduction (95% CI: 1.5–
NPC2 Replacement Therapy in NPC2-/- Mouse Model
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3.7) in lung sequestered cholesterol compared to the saline treated
NPC22/2 mice (Fig. 4). No significant difference was observed in
kidney and serum cholesterol levels among the three experimental
groups, although there was a tendency towards lower cholesterol
levels in both saline and NPC2 treated NPC22/2 mice, when
compared with the wild type controls (Fig. 4).
NPC2 treatment abrogates cholesterol storage and
visceral histopathology in vivo
The main visceral histopathological alteration in NPC disease is
an accumulation of lipid-laden foam cells in the visceral organs
[28,29,30,31]. Accordingly, hepatic H&E- and immunohisto-
chemical-staining with a macrophage specific antibody (F4/80)
revealed large numbers of sinusoidal lipid-laden Kupffer cell
clusters in tissue sections from saline treated NPC22/2 mice. In
contrast, the histological changes were minimal in liver sections
from NPC2 treated NPC22/2 mice, which showed no significant
lipid accumulation or gross pathological changes and instead
appeared much similar to liver sections from age-matched wild
type mice (Fig. 5). Masson-Trichrome staining revealed perivas-
cular collagen deposition in both NPC22/2 mice and wild type
littermates. However, there was no obvious fibrosis in any of the
groups. The histopathological findings of the liver sections from
saline treated NPC22/2 mice are consistent with previous studies
of liver histopathology in NPC12/2 mice [30,31]. Similar to the
liver, H&E staining of spleen tissue sections revealed a marked
NPC2-dependent reduction in histiocyte infiltration (Fig. 6). Saline
treated NPC22/2 mice had intra-alveolar and interstitial accumu-
lation of foamy macrophages and intra-alveolar accumulation of
Periodic Acid-Schiff (PAS) positive material (Fig. 7), consistent
with alveolar lipoproteinosis. Again, NPC2 treatment led to
reduced macrophages infiltration, a reduction in PAS-positive
material, and an overall improvement in alveolar architecture.
NPC2 treatment has insufficient effect on cholesterol
storages in affected regions of the brain
Compared to the visceral organs, a less dramatic but still
significant increase in cholesterol levels occurred in specific brain
regions from both saline and NPC2 treated NPC22/2 mice. This
was most notably the case in cerebellum and to a lesser extend in
Figure 1. Effect of purified bovine NPC2 on cholesterol accumulation in wild type and NPC22/2 fibroblasts. (A) SDS-PAGE of 5 mg
purified NPC2 resolved in a 10–20% gradient gel under nonreducing conditions and stained with Coomassie Brilliant Blue (lane 1). Molecular mass
markers are shown on the left (lane M). (B) Upper row human- (Hu) and lower row murine (Mu) fibroblasts cultivated for 48 hours in complete
medium (DMEM + 10% FBS). Wild type fibroblasts (left panels), NPC2-/- fibroblasts (middle panels), NPC2-/- fibroblasts supplemented with 600 nM NPC2
(right panels). Cells were fixed with 10% phosphate buffered formalin, pH 7.4 and stained with Filipin III and visualized using fluorescence microscope.
doi:10.1371/journal.pone.0027287.g001
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cerebral cortex. Contrary to this, no difference was found in the
levels of hippocampal cholesterol comparing the NPC22/2 and
wild type experimental groups (Fig. 8). Although not statically
significant at the 5% level, we noticed that the cerebellar
cholesterol load tended to decrease in the NPC2 treated
NPC22/2 mice (1.4 fold above wild type, 95% CI: 1.1–1.9)
compared to their saline treated hypomorph littermates (1.9 fold
above wild type, 95% CI: 1.4-2.7). The same tendency towards a
reduction in sequestered cholesterol was not observed in cortex
(Fig. 8). Our results are compatible with no effect or, at best, a
limited effect of NPC2 on cholesterol deposition in the brain under
the chosen experimental conditions.
NPC2 treatment does not influence behavioral and
neurohistopathological abnormalities in NPC22/2 mice
Homozygous NPC2-targeted mice from heterozygote mating
were born at numbers below the predicted Mendelian frequency
(n = 65 for wild type, n= 139 for heterozygous, n= 36 for NPC2-
targeted mice). The coat condition and mean body weight of both
female and male NPC22/2 mice entering the replacement trial at
p21 were similar to gender-matched wild-type mice. A progressive
decrease in relative weight gain commenced over the following
two weeks among the gene-targeted mice. However, they
presented no outward neurological signs of disease until eight
weeks of age when tremor and ataxic gait became detectable. The
motor symptoms became progressively more severe as the disease
approached end stage and euthanasia was performed.
Intravenous NPC2 treatment had no noticeable effect on gross
neurological symptoms as also the NPC2 treated NPC2-/- mice
began to display tremor and a pronounced ataxic gait at about
P60. These symptoms worsened progressively until euthanasia at
P87. In accordance, H&E-staining of the cerebellar cortex
revealed massive loss of Purkinje cell in both saline and NPC2
treated NPC22/2 mice (Fig. 9). Furthermore, marked astrocytosis
adjacent to degenerative lesions was shown by glial fibrillary acidic
protein (GFAP) immunoreactivity (Fig. 9). Several large pale cells
Figure 2. Immune response to NPC2 in 129P2 wild type- and NPC22/2 mice. NPC2 coated microtiter wells were incubated with serial
dilutions of immunized serum as indicated. Bound antibodies were detected by TRIFMA as described in Materials and Methods. An arbitrary
concentration of anti-NPC2 antibodies was set to 1000 mU/ml in positive control serum prepared by subcutaneously injections of NPC2 with
Freund’s complete adjuvant as immune potentiator. Sera from saline treated healthy mice were similarly tested and served as negative controls. (A)
Anti-NPC2 antibody concentration in intraperitoneal injected wild type mice, (B) Anti-NPC2 antibody concentration in intravenous injected wild type
mice, and (C) Anti-NPC2 antibody concentration in intravenous NPC2 treated NPC22/2 mice. Data represents mean values of triplicate wells.
doi:10.1371/journal.pone.0027287.g002
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with vacuolar cytoplasm were observed, which stained positive
with anti-F4/80 IgG. The antigenicity and morphology were
consistent with the occurrence of microglia and their numbers
were not significantly influenced by the NPC2 treatment.
Discussion
The present study is the first to report the effect of intravenous
NPC2 replacement therapy in a mouse model of NPC2 disease.
Low amounts of potentially NPC2 neutralizing antibodies were
detected in some of the NPC2 treated animals, which may have
had at least marginal influence on the efficacy of the cure.
However, no indication of anaphylaxis and no loss of animals were
observed during the trial.
The major organ sites of pathology in NPC disease are the liver,
spleen and lung, as well as the brain. Following termination of the
trial, the group receiving NPC2 therapy had pronounced lower
cholesterol levels in the liver, spleen, and lung than saline treated,
age-matched NPC22/2 control animals. Histological analysis
corroborated the biochemical results and showed a clear reduction
Figure 3. Effect of NPC2 treatment on animal body weight. (A) Males (n = 4) and (B) females (n = 6), respectively, of saline-treated wild type
mice (N), saline-treated NPC22/2 mice (#), and NPC2 treated NPC22/2 mice (.). The mice were weighed weekly from P21 to P87. Each animal was
injected twice weekly with saline or NPC2 (5 mg/kg). Values are means 6 SEM.
doi:10.1371/journal.pone.0027287.g003
Figure 4. Effect of NPC2 replacement therapy on systemic organs and serum cholesterol storage. Saline treated wild type mice (black
bars), saline treated NPC22/2mice (light gray bars), and NPC2 treated NPC22/2 mice (5 mg/kg) (dark gray bars) were injected twice weekly during the
evaluation period (P21 to P87). Post mortem total cholesterol concentrations were determined in liver, spleen, kidney, lung, and serum. Each bar
represents the mean 6 SEM measure for 6 animals in each of the experimental groups done in duplicate. Bars not sharing a letter within a given
panel are significantly different (P,0.05).
doi:10.1371/journal.pone.0027287.g004
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in the number of fat-laden cells and disease-associated macro-
phage infiltration of the NPC2 treated NPC22/2 group. We did
not find any significant variation in kidney, whole brain and serum
cholesterol comparing NPC22/2 with wild type mice. However,
measured separately, cerebellum and to a lesser extent cerebral
cortex derived from NPC22/2 mice revealed a statistically
significant increase in the proportion of cholesterol. Although we
noticed a tendency towards a cerebellar cholesterol reduction in
the NPC2 treated animals, all of the NPC22/2 mice developed
severe ataxia by the end of the treatment schedule. Histological
analysis again corroborated, by showing the same degree of
cerebellar Purkinje cells loss and astrocytosis in both NPC2 treated
and saline treated NPC22/2 mice.
It is of interest to compare our NPC2 replacement results to
other intervention studies of animal models of NPC disease. Most
striking are data demonstrating that the lipid chelator 2-
hydroxypropyl-b-cyclodextrin (CD) partially can replace the
function of NPC1 and NPC2 proteins [32], diminishes neurop-
athy, delays motor deficits, and increase median survival in both
NPC12/2 and NPC22/2 mice [13,14,33,34]. Besides the CNS
effects, the systemic response to CD seems comparable to NPC2
replacement therapy, except in the lungs where substantial cellular
cholesterol accumulation and increasing macrophage infiltration
has been observed [33]. As a result, CD treated mutant mice
developed a pulmonary alveolar proteinosis that appeared similar
to that seen in lung biopsy specimens taken from NPC2 deficient
Figure 5. Histochemical and immunohistochemical analysis of NPC2 replacement therapy in murine liver sections. Staining of
representative tissue sections of 87 days old saline treated wild type mice (left panels), saline treated NPC22/2 mice (middle panels), and NPC2 treated
NPC22/2 mice (right panels). Hematoxylin-eosin (H&E) staining (first row), immunohistochemical localisation of antigen F4/80 positive macrophages
(brownish) (second row), and Masson’s trichrome staining to detect collagen (blue) (third row). Lipid laden macrophages (Kupffer cells) are clearly
visible and prominent in liver section from saline treated NPC22/2 mice, whereas only a minority of the macrophages in liver sections from NPC2
treated NPC22/2 mice are correspondingly loaded. Data are representative of three separate experiments. n= 3 animals in each experimental group.
Scale bars represent 80 mm.
doi:10.1371/journal.pone.0027287.g005
Figure 6. Histochemical analysis of NPC2 replacement therapy in murine spleen sections. Hematoxylin-eosin (H&E) staining of spleen
from saline treated wild type mice (left panel), saline treated NPC22/2 mice (middle panel), and NPC2 treated NPC22/2 mice (right panel). Massive
accumulation of lipid droplets was most prominent observed in the spleens of saline treated NPC22/2mice. Data are representative of three separate
experiments. n=3 animals in each experimental group. Scale bares represent 100 mm.
doi:10.1371/journal.pone.0027287.g006
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infants [28,29,35]. The reason for the unresponsiveness of the
lungs towards CD is unclear, as is the mechanism by which CD
bypasses the action of NPC1 and NPC2. However, recent data
indicate that CD works from inside late endosomes/lysosomes
compartment, suggesting that endocytic uptake is significant for
CD potency [32]. Accumulation of functionally inactive, choles-
terol rich surfactant has been proposed to be the mechanism
underlying the respiratory symptoms in NPC2 disease patients
[29]. Patient’s bronchoalveolar lavage fluid reveals accumulation
of enlarged foamy and vacuolated alveolar macrophages embed-
ded in the surfactant, in keeping with their innate inability to
mobilize phagocytosed cholesterol. The implication may be that in
the affected lung environment, receptor-mediated endocytosis of
NPC2 is more efficient than fluid-phase CD pinocytosis in
enabling the macrophages to acquire the macromolecules they
needed in order to ameliorate pulmonary pathology. Alternatively,
NPC2 may have other biological functions, which influence the
phenotypic diversity observed in NPC2 and CD treated lung.
Consistent with this notion, it has recently been reported that
NPC2 deficiency in human fibroblasts confers their activation
[36]. Intriguingly, autopsy has revealed that NPC2 deficiency is
associated with pronounced pulmonary fibrosis [37], known to be
primarily mediated by activated fibroblasts [38]. Because normal-
Figure 7. Histochemical and immunohistochemical analysis of NPC2 replacement therapy in murine lung sections. Staining of
representative tissue sections from saline treated wild type mice (left panels), saline treated NPC22/2mice (middle panels), and NPC2 treated NPC22/2
mice (right panels). Hematoxylin-eosin (H&E) lung staining (first row), immunohistochemical localisation of antigen F4/80 positive macrophages
(brownish) (second and third row), and PAS-staining to detect the presence of glycogen (dark purple) (fourth row). Data are representative of three
separate experiments. n= 3 animals in each experimental group. Scale bars represent 30 mm except in second row where it equals 100 mm.
doi:10.1371/journal.pone.0027287.g007
Figure 8. Effect of NPC2 replacement therapy on murine brain
cholesterol storage. Total cholesterol levels in cerebellum, cortex,
and hippocampus was measured postmortem in saline treated wild
type mice (black bars), saline treated NPC22/2mice (light gray bars), and
NPC2 treated NPC22/2 mice (dark gray). Each bar represents the mean
6 SEM for 6 animals in each of the three groups. Bars not sharing a
letter within a given panel are significantly different (P,0.05).
doi:10.1371/journal.pone.0027287.g008
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ization of cholesterol in the NPC22/2 fibroblasts failed to correct
their activated phenotype [36], it is possible that the ameliorating
effect experienced by NPC2 therapy is independent of its function
in intracellular cholesterol trafficking. The latter is in line with new
and interesting studies, highlighting NPC2 as a potentially multi-
functional protein involved in a number of regulatory processes,
including hematopoiesis [39], immunity [40], somatic cell
plasticity and adipogenesis [36,41], and in papillae formation
[42], all apparently independent of NPC2 cholesterol binding
ability. Furthermore, a positive correlation between extracellular
NPC2 and cholesterol biliary secretion has been reported [43].
Therefore, a well-grounded decision on the basis of the alleviating
effects of NPC2 replacement has to await further investigation into
the cholesterol transport dependent and independent activity of
the protein.
Although the majority of data implicate cholesterol accumula-
tion as the primary defect in NPC disease, biochemical analyses of
lipid extract from human and murine NPC brains have revealed
increased levels of glycolipids [44]. Thus, a second therapeutic
agent successfully tested in animal models of NPC disease is
miglustat (N-butyl-deoxynojirimycin, ZavescaH), an imino sugar-
based inhibitor of the glycosphingolipid biosynthetic pathway [45].
Animal models responded positively to treatment, resulting in
reduced ganglioside accumulation, delayed onset of neurological
symptoms, increased Purkinje cell survival, and extended animal
life span [46]. In Europe, miglustat, has recently been approved
for specific treatment of the neurological manifestations in NPC
disease and clinical trials have demonstrated a mild clinical
neurological improvement or stabilization, but did not indicate
clinically relevant systemic organ effects, where cholesterol
accumulation was almost unaffected [11,12,47]. Considering
NPC2 replacement therapy ameliorates the lung and visceral
complications experienced by our animal model of NPC2 disease
as well as affected patients, we submit that a combination of NPC2
and CD and/or miglustat may represent a highly attractive novel
therapeutic intervention for the handful of patients suffering from
NPC2 disease.
The NPC2 treatment led to no obvious improvements in CNS
disease. This is likely due to the inability of the injected NPC2
protein to cross the blood brain barrier (BBB), which restricts the
passage of proteins into and out of the brain parenchyma [48,49].
The NPC2 replacement therapy was initiated three weeks after
birth, which may have reduced its therapeutic potential in the
CNS. This is underlined by prior preclinical studies in mouse
models showing M6P-containing enzymes cross the neonatal BBB
through a developmentally regulated M6P-receptor-mediated
transport mechanism [50]. As the M6P-receptor-dependent
transport across the BBB in mice is discontinued after about two
weeks postpartum [51], the fact that NPC2 therapy with the M6P-
tagged NPC2 [4] did not stall CNS degeneration may relate to the
onset of the treatment. Two strategies have previously been used
to overcome the decreased expression of M6P-receptor; 1) high
dose replacement therapy, e.g. in a mouse model of adult
mucopolysaccharidosis type VII [52], and 2) induction of M6P-
receptor expression using epinephrine which appears to restore
transport kinetics to the postnatal state [53]. Whether adoption of
such strategies would have any impact on the manifestations of the
neurodegenerative process is an important question that needs to
be answered by further research. Notable, although we have found
that milk derived NPC2 is able to bind the cation-independent
M6P-receptor, the rate of M6P-receptor internalization vary
depending on the mannose phosphorylation status of the ligand.
Figure 9. Histochemical and immunohistochemical staining of cerebellum. Staining of representative cerebellum sections from saline-
treated wild type mice (left panels), saline treated NPC22/2 mice (middle panels), and NPC2 treated NPC22/2 mice (right panels). Hematoxylin-eosin
(H&E) staining (first row), immunohistochemical GFAP-staining for detection of astrocytes (brownish) (second row), and immunohistochemical
localisation of antigen F4/80 positive macrophages (brownish) (third row). Data are representative of three separate experiments. n=3 animals in
each experimental group. Scale bars represent 30 mm.
doi:10.1371/journal.pone.0027287.g009
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As the intrinsic affinity of NPC2 for the M6P-receptors is
unknown, our current data do not allow us to conclude whether
the NPC2 is transported to lysosomes via the M6P-receptor, in an
M6P-independent manner mediated by alternative receptors, or
by fluid-phase pinocytosis. Regardless, an alternative delivery
strategy is to bypass the BBB by direct injections into the cerebral
circulation, which previously has been exploited successfully in
other models of neurodegenerative lysosomal storages diseases
[54,55].
Minimal changes in whole brain cholesterol have been reported
in NPC12/2 mice and previous studies showed that cholesterol
levels in brains are similar to, if not lower, compared with levels
observed in wild type mice [56,57]. We extended previous
investigations on whole NPC12/2 brain by investigating the
cholesterol levels in three different regions of the NPC22/2 brain
(cerebellum, cortex, and hippocampus). These data revealed that
the cholesterol level of hippocampus is similar among NPC2
deficient- and wild type mice. There was a marginal increase in
the cholesterol pool of the cortex in NPC22/2 mice, whereas
cerebellum revealed a more clear-cut cholesterol excess compared
to wild-type brains. Recently, Bi and coworkers reported that
cholesterol accumulation resulting from lack of functional NPC1
protein occurs not only in neurons but also in microglia [58].
These observations are in line with our results as microglia
infiltration was observed in cerebellum of NPC22/2 mice.
Whether glial activation represents a reactive response to neuronal
damage, or results from intrinsic alterations due to NPC2
deficiency remains undetermined. The finding that cholesterol is
significant elevated in cerebellum may appear in discord with
previous reports based on NPC12/2 whole brain homogenates.
However, considering the weight of the adult mouse cerebellum
constitutes ,10% of whole brain weight, it may not be surprising
that the mean increase of total cholesterol in this region of the
brain do not significantly contribute to the overall measurement of
cholesterol in the whole brain. In support of this, progressive
accumulation of cholesterol as detected by staining with the
fluorescent dye filipin has recently been observed in cerebellum
sections from in NPC12/2 mice [59]. The targeted rescue of the
visceral organs in the NPC22/2 mouse allowed us to observe the
benefits systemic improvements alone could have on neurodegen-
eration NPC disease. Based on our data it seems likely that the
neurodegenerative effects observed is a direct effect of NPC2
deficiency and not a secondary metabolic side effect in response to
e.g. liver damage.
Conclusion
We present data from preclinical studies that regular intrave-
nous administrations of NPC2 ameliorate many of the visceral
changes caused by loss of functional NPC2 protein. Thus, systemic
delivery of NPC2 seems a promising option for treating the non-
cerebral complications in NPC2 disease, which may be readily
translatable to the clinical setting. In particular, this therapeutic
approach may be suitable for patients who experience chronic
respiratory and liver failure in early infancy for which there is
currently no adequate therapeutic approach. It remains to be
investigated whether improved efficiency of administered NPC2 to
relieve the cerebral symptoms can be gained by changes in route of
administration, dose level, or therapy onset. The two latter have
previously been shown to influence survival time in CD treated
NPC12/2 mice [14]. Furthermore, intrathecal administration of
CD in a feline model harboring a missense mutation in NPC1 has
recently been shown to better ameliorate aspects of the
neurological disease and extend lifespan when compared to
systemic injection [60]. It remains to be seen if the intrathecal
applicable strategy is a potential avenue for NPC2 replacement in
CNS as well.
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